Potent and selective N-(4-sulfamoylphenyl)thiourea-based GPR55 agonists

European Journal of Medicinal Chemistry

Volumn 107, Issue , 2016, Pages 119-132

  Yrjölä, Sari ^a   Parkkari, Teija ^a   Navia Paldanius, Dina ^a   Laitinen, Tuomo ^a   Kaczor, Agnieszka A ^a,b   Kokkola, Tarja ^a   Adusei Mensah, Frank ^a   Savinainen, Juha R ^a   Laitinen, Jarmo T ^a   Poso, Antti ^a,c   Alexander, Amy ^d   Penman, June ^d   Stott, Lisa ^d   Anskat, Marie ^d   Irving, Andrew J ^d,e   Nevalainen, Tapio J ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

G protein coupled receptor 55; Molecular modeling; Structure activity relationships

Indexed keywords

4 AMINO N BENZYLBENZAMIDE; 4 AMINO N BENZYLBENZENESULFONAMIDE; 4 AMINO N ISOBUTYLBENZENESULFONAMIDE; 4 AMINO N PHENYLBENZENESULFONAMIDE; 4 AMINO N PROPYLBENZENESULFONAMIDE; 4 AMINO N(4 FLUOROBENZYL)BENZENESULFONAMIDE; 4 AMINO N(4 IODOBENZYL)BENZENESULFONAMIDE; 4 AMINO N(4 METHOXYBENZYL)BENZENESULFONAMIDE; 4 NITRO N PHENETHYLBENZAMIDE; 4 NITRO N PHENETHYLBENZENESULFONAMIDE; 4 NITRO N PHENYLBENZENESULFONAMIDE; 4 NITRO N PROPYLBENZENESULFONAMIDE; CANNABINOID RECEPTOR AGONIST; CID 1011163; CID 1252842; CID 1792579; G PROTEIN COUPLED RECEPTOR 55 AGONIST; N ALLYL 4 NITROBENZENESULFONAMIDE; N BENZYL 4 NITROBENZAMIDE; N ISOBUTYL 4 NITROBENZENESULFONAMIDE; N(4 BUTYLPHENYL) 4 NITROBENZENESULFONAMIDE; N(4 CHLOROPHENYL) 4 NITROBENZENESULFONAMIDE; N(4 FLUOROBENZYL) 4 NITROBENZENESULFONAMIDE; N(4 IODOBENZYL) 4 NITROBENZENESULFONAMIDE; N(4 METHOXYBENZYL) 4 NITROBENZENESULFONAMIDE; N(4 METHYLBENZYL) 4 NITROBENZENESULFONAMIDE; N(FURAN 2 YLMETHYL) 4 NITROBENZENESULFONAMIDE; N,N DIALLYL 4 NITROBENZENESULFONAMIDE; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ABHD12 PROTEIN, HUMAN; ABHD6 PROTEIN, HUMAN; ACYLGLYCEROL LIPASE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; GPR55 PROTEIN, HUMAN; LIGAND; THIOUREA;

ARTICLE; BIOASSAY; CALCIUM SIGNALING; COMPARATIVE MOLECULAR FIELD ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; EC50; HUMAN; HUMAN CELL; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION; AGONISTS; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; METABOLISM; PRECLINICAL STUDY; PROCEDURES; SYNTHESIS;

CELL LINE; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENDOCANNABINOIDS; HUMANS; LIGANDS; MODELS, MOLECULAR; MONOACYLGLYCEROL LIPASES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP; THIOUREA;

EID: 84946935204     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.10.050     Document Type: Article

References (54)

1. R.A. Ross, The enigmatic pharmacology of GPR55, Trends Pharmacol. Sci. 30 (3) (2009) 156-163.
2. S. Oka, K. Nakajima, A. Yamashita, S. Kishimoto, T. Sugiura, Identification of GPR55 as a lysophosphatidylinositol receptor, Biochem. Biophys. Res. Commun. 362 (4) (2007) 928-934.
3. S. Oka, T. Toshida, K. Maruyama, K. Nakajima, A. Yamashita, T. Sugiura, 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55, J. Biochem. 145 (1) (2009) 13-20.
4. A. Kapur, P. Zhao, H. Sharir, Y. Bai, M.G. Caron, L.S. Barak, M.E. Abood, Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands, J. Biol. Chem. 284 (43) (2009) 29817-29827.
5. P. Zhao, M.E. Abood, GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors, Life Sci. 92 (8-9) (2013) 453-457.
6. A. Moriconi, I. Cerbara, M. Maccarrone, A. Topai, GPR55: current knowledge and future perspectives of a purported "type-3" cannabinoid receptor, Curr. Med. Chem. 17 (14) (2010) 1411-1429.
7. P.C. Staton, J.P. Hatcher, D.J. Walker, A.D. Morrison, E.M. Shapland, J.P. Hughes, E. Chong, P.K. Mander, P.J. Green, A. Billinton, M. Fulleylove, H.C. Lancaster, J.C. Smith, L.T. Bailey, A. Wise, A.J. Brown, J.C. Richardson, I.P. Chessell, The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain, Pain 139 (1) (2008) 225-236.
8. N.A. Balenga, E. Aflaki, J. Kargl, W. Platzer, R. Schroder, S. Blattermann, E. Kostenis, A.J. Brown, A. Heinemann, M. Waldhoer, GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils, Cell Res. 21 (10) (2011) 1452-1469.
9. M. Pietr, E. Kozela, R. Levy, N. Rimmerman, Y.H. Lin, N. Stella, Z. Vogel, A. Juknat, Differential changes in GPR55 during microglial cell activation, FEBS Lett. 583 (2009) 2071-2076.
10. S. Sylantyev, T.P. Jensen, R.A. Ross, D.A. Rusakov, Cannabinoid-and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses, Proc. Natl. Acad. Sci. U. S. A. 110 (13) (2013) 5193-5198.
11. L.S. Whyte, E. Ryberg, N.A. Sims, S.A. Ridge, K. Mackie, P.J. Greasley, R.A. Ross, M.J. Rogers, The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo, PNAS 106 (38) (2009) 16511-16516.
12. L.A. Ford, A.J. Roelofs, S. Anavi-Goffer, L. Mowat, D.G. Simpson, A.J. Irving, M.J. Rogers, A.M. Rajnicek, R.A. Ross, A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells, Br. J. Pharmacol. 160 (3) (2010) 762-771.
13. C. Andradas, M.M. Caffarel, E. P-erez-G-omez, M. Salazar, M. Lorente, G. Velasco, M. Guzm-an, C. S-anchez, The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK, Oncogene 30 (2) (2011) 245-252.
14. R. Pi~neiro, T. Maffucci, M. Falasca, The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation, Oncogene 30 (2) (2011) 142-152.
15. L. Huang, J.C. Ramirez, G.A. Frampton, L.E. Golden, M.A. Quinn, H.Y. Pae, D. Horvat, L.J. Liang, S. DeMorrow, Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor, Lab. Invest 91 (7) (2011) 1007-1017.
16. R. Schicho, M. Storr, A potential role for GPR55 in gastrointestinal functions, Curr. Opin. Pharmacol. 12 (6) (2012) 653-658.
17. J.M. Moreno-Navarrete, V. Catal-an, L. Whyte, A. Diáz-Arteaga, R. V-azquez-Martínez, F. Rotellar, R. Guzm-an, J. G-omez-Ambrosi, M.R. Pulido, W.R. Russell, M. Imbern-on, R.A. Ross, M.M. Malag-on, C. Dieguez, J.M. Fern-andez-Real, G. Frühbeck, R. Nogueiras, The L-a-lysophosphatidylinositol/GPR55 system and its potential role in human obesity, Diabetes 61 (2) (2012) 281-291.
18. H. Ishiguro, E.S. Onaivi, Y. Horiuchi, K. Imai, G. Komaki, T. Ishikawa, M. Suzuki, Y. Watanabe, T. Ando, S. Higuchi, T. Arinami, Functional polymorphism in the GPR55 gene is associated with anorexia nervosa, Synapse 65 (2) (2011) 103-108.
19. A. Bondarenko, M. Waldeck-Weiermair, S. Naghdi, M. Poteser, R. Malli, W.F. Graier, GPR55-dependent and-independent ion signalling in response to lysophosphatidylinositol in endothelial cells, Br. J. Pharmacol. 161 (2) (2010) 308-320.
20. S. Heynen-Genel, R. Dahl, S. Shi, L. Milan, S. Hariharan, Y. Bravo, E. Sergienko, M. Hedrick, S. Dad, D. Stonich, Y. Su, M. Vicchiarelli, A. Mangravita-Novo, L.H. Smith, T.D.Y. Chung, H. Sharir, L.S. Barak, M.E. Abood, Screening for selective ligands for GPR55-agonists [Updated 2011 May 26], in: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD), National Center for Biotechnology Information, US, 2010. Available from: http://www. ncbi.nlm.nih.gov/books/NBK66152/.
21. National Center for Biotechnology Information. PubChem BioAssay Database; AID1961, Source: Burnham Center for Chemical Genomics (BCCG-a221-GPR55-agonist-assay), http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi aid1961 (accessed 10.04.13.).
22. E. Kotsikorou, K.E. Madrigal, D.P. Hurst, H. Sharir, D.L. Lynch, S. Heynen-Genel, L.B. Milan, T.D. Chung, H.H. Seltzman, Y. Bai, M.G. Caron, L. Barak, M.E. Abood, P.H. Reggio, Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands, Biochemistry 50 (25) (2011) 5633-5647.
23. A.J. Brown, D.A. Daniels, M. Kassim, S. Brown, C.P. Haslam, V.R. Terrell, J. Brown, P.L. Nichols, P.C. Staton, A. Wise, S.J. Dowell, Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist, J. Pharmacol. Exp. Ther. 337 (1) (2011) 236-246.
24. J. Kargl, A.J. Brown, L. Andersen, G. Dorn, R. Schicho, M. Waldhoer, A. Heinemann, A selective antagonist reveals a potential role of g proteincoupled receptor 55 in platelet and endothelial cell function, J. Pharmacol. Exp. Ther. 346 (1) (2013) 54-66.
25. S. Heynen-Genel, R. Dahl, S. Shi, L. Milan, S. Hariharan, E. Sergienko, M. Hedrick, S. Dad, D. Stonich, Y. Su, M. Vicchiarelli, A. Mangravita-Novo, L.H. Smith, T.D.Y. Chung, H. Sharir, M.G. Caron, L.S. Barak, M.E. Abood, Screening for Selective Ligands for GPR55-antagonists. Probe Reports from the NIH Molecular Libraries Program [Internet], National Center for Biotechnology Information (US), Bethesda (MD), 2010.
26. E. Kotsikorou, H. Sharir, D.M. Shore, D.P. Hurst, D.L. Lynch, K.E. Madrigal, S. Heynen-Genel, L.B. Milan, T.D. Chung, H.H. Seltzman, Y. Bai, M.G. Caron, L.S. Barak, M.P. Croatt, M.E. Abood, P.H. Reggio, Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands, Biochemistry 52 (52) (2013) 9456-9469.
27. V. Rempel, N. Volz, F. Glaser, M. Nieger, S. Brase, C.E. Müller, Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold, J. Med. Chem. 56 (11) (2013) 4798-4810.
28. V. Rempel, A. Fuchs, S. Hinz, T. Karcz, M. Lehr, U. Koetter, C.E. Müller, Magnolia extract, magnolol, and metabolites: activation of cannabinoid CB2 receptors and blockade of the related GPR55, ACS Med. Chem. Lett. 4 (1) (2013) 41-45.
29. C.M. Henstridge, N.A. Balenga, L.A. Ford, R.A. Ross, M. Waldhoer, A.J. Irving, The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoAdependent Ca2\+ signaling and NFAT activation, FASEB J. 23 (1) (2009) 183-193.
30. A. Le Pera, A. Leggio, A. Liguori, Highly specific N-monomethylation of primary aromatic amines, Tetrahedron 62 (25) (2006) 6100-6106.
31. M. Kapischke, T. Fischer, K. Tiessen, H. Tschesche, H.P. Bruch, H. Kalthoff, M.L. Kruse, Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in vitro and in an orthotopic pancreatic cancer model in vivo, Int. J. Oncol. 32 (1) (2008) 273-282.
32. K. Namba, X. Zheng, K. Motoshima, H. Kobayashi, A. Tai, E. Takahashi, K. Sasaki, K. Okamoto, H. Kakuta, Design and synthesis of benzenesulfonanilides active against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, Bioorg. Med. Chem. 16 (11) (2008) 6131-6144.
33. C.K. Ozer, H. Arslan, D. VanDerveer, N. Külcü, Synthesis and characterization of N-(arylcarbamothioyl)-cyclohexanecarboxamide derivatives: the crystal structure of N-(naphthalen-1-ylcarbamothioyl)cyclohexanecarboxamide, Molecules 14 (2) (2009) 655-666.
34. M.K. Rauf, Imtiaz-ud-Din, A. Badshah, M. Gielen, M. Ebihara, D.D. Vos, S. Ahmed, Synthesis, structural characterization and in vitro cytotoxicity and anti-bacterial activity of some copper(I) complexes with N,N0-disubstituted thioureas, J. Inorg. Biochem. 103 (8) (2009) 1135-1144.
35. M.N.S. Rad, A. Khalafi-Nezhad, Z. Asrari, S. Behrouz, Z. Amini, M. Behrouz, Onepot synthesis of sulfonamides from primary and secondary amine derived sulfonate salts using cyanuric chloride, Synthesis 23 (2009) 3983-3988.
36. SYBYL-X 2.1, Tripos International, St. Louis, MO, 2011.
37. Schrodinger Suite 2014-1, Induced Fit Docking Protocol; Glide Version 6.2, Prime Version 3.5, Schrodinger, LLC, New York, NY, 2014.
38. Molecular Operating Environment (MOE) software, http://www.chemcomp. com/software.htm.
39. S.G. Rasmussen, B.T. DeVree, Y. Zou, A.C. Kruse, K.Y. Chung, T.S. Kobilka, F.S. Thian, P.S. Chae, E. Pardon, D. Calinski, J.M. Mathiesen, S.T. Shah, J.A. Lyons, M. Caffrey, S.H. Gellman, J. Steyaert, G. Skiniotis, W.I. Weis, R.K. Sunahara, B.K. Kobilka, Crystal structure of the b2 adrenergic receptor-Gs protein complex, Nature 477 (2011) 549-555.
40. N. Eswar, M.A. Marti-Renom, B. Webb, M.S. Madhusudhan, D. Eramian, M. Shen, U. Pieper, A. Sali, Comparative protein structure modeling with MODELLER, in: Current Protocols in Bioinformatics, John Wiley & Sons, Inc., 2006. Supplement 15, 5.6.1-5.6.30.
41. M.Y. Shen, A. Sali, Statistical potential for assessment and prediction of protein structures, Protein Sci. 15 (2006) 2507-2524.
42. F. Melo, E. Feytmans, E. Assessing protein structures with a non-local atomic interaction energy, J. Mol. Biol. 277 (1998) 1141-1152.
43. J.U. Bowie, R. Lüthy, D.A. Eisenberg, A method to identify protein sequences that fold into a known three-dimensional structure, Science 253 (1991) 164-170.
44. R.A. Laskowski, M.W. MacArthur, D.S. Moss, J.M. Thornton, PROCHECK e a program to check the stereochemical quality of protein structures, J. App. Cryst. 26 (1993) 283-291.
45. The PyMOL Molecular Graphics System, Version 1.5.0.3, Schrodinger, LLC.
46. N. Guex, M.C. Peitsch, SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling, Electrophoresis 18 (1997) 2714-2723.
47. Schrodinger Release 2014-1, Jaguar, Version 8.3, Schrodinger, LLC, New York, NY, 2014.
48. Schrodinger Suite 2014-1, Protein Preparation Wizard; Epik Version 2.7, Impact Version 6.2, Schrodinger, LLC, New York, NY, 2014. Prime version 3.5.
49. R.D. Cramer, D.E. Patterson, J.D. Bunce, Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins, J. Am. Chem. Soc. 110 (1988) 5959-5967.
50. J.R. Savinainen, S.M. Saario, R. Niemi, T. Jarvinen, J.T. Laitinen, An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors, Br. J. Pharmacol. 140 (2003) 1451-1459.
51. J.R. Savinainen, T. Kokkola, O.M.H. Salo, A. Poso, T. Jarvinen, J.T. Laitinen, Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor, Br. J. Pharmacol. 145 (2005) 636-645.
52. S.M. Saario, A. Poso, R.O. Juvonen, T. Jarvinen, O.M. Salo-Ahen, Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system, J. Med. Chem. 49 (15) (2006) 4650-4656.
53. A. Minkkila, S.M. Saario, H. Kasnanen, J. Leppanen, A. Poso, T. Nevalainen, Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase, J. Med. Chem. 51 (2008) 7057-7060.
54. D. Navia-Paldanius, J.R. Savinainen, J.T. Laitinen, Biochemical and pharmacological characterization of human a/b-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12), J. Lipid. Res. 53 (2012) 2413-2424.